Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Henan Taloph Pharmaceutical Stock Co.,Ltd (600222.SS)
Zhengzhou, CN
Operating from Zhengzhou, China, Henan Taloph Pharmaceutical Stock Co., Ltd. specializes in the research, development, production, and sale of a wide array of Chinese and Western medicines across the nation. The company's product line encompasses various forms, such as oral liquids, tablets, capsules, and injectable fluids. Notable products include Huperzine A tablets, phenoxybenzamine hydrochloride tablets, and pazufloxacin mesylate sodium chloride injections, alongside a selection of other infusion products. Taloph Pharmaceutical serves a diverse client base, including hospitals, pharmacies, and direct consumers. It was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.89% | -2.87% | +14.56% | +6.71% | -3.11% | +18.39% | +39.61% | +28.55% | +18.93% | +4.70% | +85.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-9.5% Q1'26: +8.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+21.2% ★ Q1'26: +67.9% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-4.0% Q1'26: -57.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.2% Q1'26: +3.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.1% Q1'26: +1.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.6% ★ Q1'26: +1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×6.56× Q1'26: 20.76× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
1.19B
est: 1.21B (-1.3%)
|
1.31B
est: 1.35B (-3.1%)
|
| EBITDA |
-5.59M
est: 76.64M (-107.3%)
|
85.50M
est: 85.65M (-0.2%)
|
| EBIT |
-56.88M
est: 37.10M (-253.3%)
|
47.32M
est: 41.46M (+14.1%)
|
| Net Income |
-115.32M
|
44.41M
|
| SGA |
252.41M
est: 99.48M (+153.7%)
|
293.07M
est: 111.18M (+163.6%)
|
| EPS |
-0.20
|
0.08
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 6.2K | 0.48% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 13.9K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 686.8K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.1K | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.3K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.8K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 787.48 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 90.93 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 29.88 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 14.23 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Yun Chen | Accounting Supervisor & Employee Representative Director | — | female |
| Fengshan Su | Executive Vice General Manager | — | male |
| Hailin Zhao | CFO & Deputy GM | — | male |
| Jingliang Li | GM & Vice Chairman | — | male |
| Lizhuang Zhang | Deputy General Manager | — | male |
| Nianyun Li | Deputy GM & Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600222.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
